FeesSafety
Pluang+

Law firm probes Coastal Financial after $42.1M Q2 loss and 43.5% stock plunge.

Market News
14 Sep 2026
Newsfile Corp
View Source
Bearish
Law firm probes Coastal Financial after $42.1M Q2 loss and 43.5% stock plunge.

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Coastal Financial Corporation following the company's report of a $42.1 million net loss in Q2 2026, largely due to a $68.8 million credit expense linked to a single partner. This loss caused Coastal's stock to drop 43.5% in one day. The investigation seeks to determine if Coastal misled investors, with Kaplan Fox inviting affected investors to come forward. The outcome could impact shareholder recoveries and corporate accountability.

Coastal Financial Corporation's recent $42.1 million net loss and subsequent stock drop of 43.5% provide context for this investigation news. For readers following the Financials sector, here is Pluang's market snapshot as of Sep 15, 2026 02:22 WIB: out of 74 priced US Financials stocks tradable on Pluang, 28 rose and 46 fell today. Notable price changes include AVAT at USD 0.98 (-3.06%), DB at USD 39.28 (-2.96%), and AFRM at USD 73.12 (+2.35%).

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
48 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App